Florida-based wealth advisory J. L. Bainbridge disclosed a purchase of Eli Lilly and Company valued at approximately $45.6 ...

Trump told reporters late Thursday that the list price of Ozempic, which he called “the fat loss drug,” will be “much lower.” ...

Since then, supply has returned thanks to Lilly's investments in manufacturing and a move to also offer Zepbound, previously ...

Eli Lilly's Mounjaro clocked in ₹80 crore in September, second only to India’s leading brand of the month, GSK’s Augmentin, ...

By Stine Jacobsen and Bhanvi Satija COPENHAGEN (Reuters) -Shares of weight-loss drug makers Novo Nordisk and Eli Lilly fell ...

What is the ‘golden dose’ and what are the risks? Medical News Today asks four experts to weigh in on the trend of trying to ...

Eli Lilly's blockbuster GLP-1 drugs, Mounjaro and Zepbound, are driving explosive growth as the company prepares to report Q3 ...

Eli Lilly and Company's strong Phase 3 diabetes drug results boost its GLP-1 franchise. Click for my updated look at LLY ...

South Africa's Aspen Pharmacare said on Monday it had secured regulatory approval to market Eli Lilly's blockbuster diabetes ...

Eli Lilly shares are trading lower Friday, among other GLP-1 drug manufacturers, following Trump's comments that fat-loss ...

According to PharmaTrac data for September 2025, Mounjaro clocked ₹80 crore in monthly sales - just behind GSK’s Augmentin at ...